Simplify Logo

Full-Time

Senior Product Manager

HCP Marketing

Posted on 7/24/2024

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Develops therapies for CNS disorders

Hardware
Biotechnology

Compensation Overview

$140k - $160kAnnually

+ Bonus + Equity

Senior

New York, NY, USA

Category
Product Marketing
Product
Required Skills
Market Research
Sales
Marketing
Data Analysis
Requirements
  • BA or BS required; advanced degree preferred
  • Migraine experience strongly preferred
  • Minimum 4-5 years of experience in pharmaceutical/biotechnology marketing, with a minimum of 2-3 years of experience successfully executing HCP-focused campaigns
  • Ability to work on site Monday, Tuesday & Thursday
Responsibilities
  • Contribute to the development of the marketing plans for AXS-07 and champion the plan through engagement with internal and external partners
  • Lead portions of the development of the integrated brand plan, create programs and tactics to support the strategy, and execute the tactical marketing plans focused on HCP audiences
  • Identify appropriate measurements & ROI, and develop comprehensive reporting to evaluate effectiveness of tactical efforts
  • Effectively manage key agency partners
  • Lead reviews of promotional materials with Regulatory/Legal/Medical
  • Collaborate effectively with sales & marketing, market access, market research, medical affairs, commercial operations, data & analytics, finance, and other cross-functional partners
  • Identify strategic market opportunities and make recommendations to enhance brand penetration
  • Develop mid- to long-range plan for future indications
  • Manage timelines and budgets in accordance with brand plan
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

92%

1 year growth

92%

2 year growth

92%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.
INACTIVE